COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Hyperbaric Oxygen Therapy (HBOT) for Chronic Diabetic Lower Limb Ulcers (HBOT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00621608
Recruitment Status : Completed
First Posted : February 22, 2008
Last Update Posted : May 9, 2013
Judy Dan Research and Treatment Centre Ontario Wound Care Inc
University Health Network, Toronto
Information provided by (Responsible Party):
Ron Goeree, St. Joseph's Healthcare Hamilton

Brief Summary:
The purpose of this study is to determine if HBOT plus standard wound care is more effective than standard wound care alone at preventing the need for major amputation (metatarsal and up) in patients with diabetes mellitus (Type 1 or 2) with moderate to sever chronic wounds of lower limbs.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus Chronic Ulcers of the Lower Limb Procedure: Hyperbaric Oxygen Therapy Procedure: Placebo Hyperbaric Oxygen Chamber Phase 4

Detailed Description:
People with diabetes mellitus and non-healing ulcers of the lower limb are at higher risk of amputation. Current standard care for foot ulcers includes maintaining optimal blood glucose levels, use of debridement, antibacterials, dressings, antibiotics for infection; adequate nutrition; pressure relief and amputation. There has been an increased interest in the use of hyperbaric oxygen therapy (HBOT) as an adjunctive treatment for diabetic ulcers. HBOT is an established technology which currently is an accepted treatment of chronic diabetic ulcers in Ontario and physicians who provide this service are reimbursed under the current Ontario Health Insurance Plan (OHIP). However there are only a few facilities that can provide this service. In addition, results of published HBOT studies are inconsistent. The current study will provide quality efficacy data on the use of HBOT as an adjunctive therapy. As this study has been recommended by the Ontario Health Technology Advisory Committee (OHTAC), the results of the study will be used to make policy decisions regarding the funding and further utilization of HBOT therapy for people with diabetes mellitus with ulcers of the lower limb in the province. If the results are favorable towards HBOT in the treatment of diabetic ulcers, potential expansion and availability of this and other programs maybe be possible. A randomized placebo control trial evaluating HBOT, to the best of our knowledge has not been completed in this area and will provide much needed information to the scientific community.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 107 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective, Double-blind, Randomized, Controlled Clinical Trial Comparing Standard Wound Care With Adjunctive Hyperbaric Oxygen Therapy (HBOT) to Standard Wound Care Only for the Treatment of Chronic, Non-healing Ulcers of the Lower Limb in Patients With Diabetes Mellitus.
Study Start Date : April 2008
Actual Primary Completion Date : March 2013
Actual Study Completion Date : April 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
Hyperbaric Oxygen Therapy
Procedure: Hyperbaric Oxygen Therapy
Hyperbaric Oxygen Therapy (HBOT) will be provided 5 days per week for 6 weeks for a total of 30 treatments on average. Subjects will be placed into the hyperbaric chamber for approximately 90 minutes of HBOT at 2.4 ATA (partial pressure of oxygen = 1,800 mmHg) when inside the chamber. Subjects will receive dressing changes as required per standard of care.

Sham Comparator: 2
Placebo Hyperbaric Oxygen Chamber
Procedure: Placebo Hyperbaric Oxygen Chamber
Patients will receive HBOT placebo 5 days per week for 6 weeks for a total of 30 treatments. Each patient will be placed into the hyperbaric chamber and will receive 90 minutes of room air while inside the chamber and the initial flow of air into the chamber will produce a small increase in pressure (0.3 ATA partial pressure of oxygen = 210 mmHg) which will then be released over a period of 10 minutes. Subjects will receive dressings changes as required per standard of care.

Primary Outcome Measures :
  1. Freedom from having, or meeting the criteria for, a major amputation (below knee amputation, or metatarsal level) up to 12 weeks after randomization. [ Time Frame: up to 12 weeks after randomization ]

Secondary Outcome Measures :
  1. Wound healing: difference in wound measurements (i.e. depth, length, width and extent of surface area); reduction in Wagner Classification Score; proportion of wound closed at 12 weeks of any time interval prior to end point; time to healing (days) [ Time Frame: up to 12 weeks after randomization ]
  2. Effectiveness: maintenance on therapy (discontinuation rates); and secondary prevention interventions (confounding variables that may influence primary outcome such as diabetes control) [ Time Frame: up to 12 weeks after Randomziation ]
  3. Safety: Major morbidity (infection requiring hospitalization, renal failure); wound interventions during study (debridement, surgery); Complications related to HBOT (seizure, pulmonary syndromes, vision disturbance; and all cause mortality [ Time Frame: From enrollment up to 1 year after randomization ]
  4. Healthcare resource utilization: wound dressing materials; healthcare provider visits; inpatient hospital admissions; complex continuing care/rehabilitation; drug therapy; mobility assistive devices [ Time Frame: From enrollment to study up to 1 year after randomization ]
  5. Quality of life: assessed by Standard Form 36 (SF-36) domain scores; EuroQoL 5D (EQ-5D) summary scores and by the Diabetic Foot Ulcer-Short Form (DFS-SF) scores [ Time Frame: Baseline, end of treatment, end of follow-up, and EQ5D only at 6 and 12 months ]
  6. Cost effectiveness of HBOT: calculate the incremental cost per amputation avoided and the incremental cost per quality-adjusted life-year (QALY) gained [ Time Frame: From Enrollment to 1 year after randomization ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age > 18 years
  • Type 1 or 2 Diabetes Mellitus
  • Wagner grading of foot lesions 3 or 4 on lower limb not healing for 4 weeks.

Exclusion Criteria:

  • Impending urgent amputation due to ongoing or exacerbated infection;
  • Exposed calcaneus bone with no prospect of weight bearing potential even if defect has been healed;
  • Dialysis-dependent renal failure;
  • Any of the following medical conditions which preclude safe treatment in a monoplace chamber: clinical depression; severe dementia; claustrophobia; seizure disorder; active asthma; severe chronic obstructive pulmonary disease; previous thoracic surgery; previous spontaneous or trauma induced pneumothorax; history of severe congestive heart failure with left ventricular ejection fraction less than 20%; unstable angina; chronic sinusitis; chronic or acute otitis media or major ear drum trauma; severe kyphoscoliosis; arthritis; or morbid obesity;
  • History of chemotherapy with use of Bleomycin;
  • Participation in another investigative drug or device trial currently or within the last 30 days;
  • Current candidates for vascular surgery, angioplasty or stenting;
  • Major large vessel disease;
  • Undergone vascular surgery or angioplasty within the last 3 months;
  • Women who are currently pregnant or are breast feeding or women of childbearing potential who are not currently taking adequate birth control.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00621608

Layout table for location information
Canada, Ontario
Judy Dan Wound Care Centre/University Health Network
Toronto, Ontario, Canada, M2R 1N5
Sponsors and Collaborators
St. Joseph's Healthcare Hamilton
Judy Dan Research and Treatment Centre Ontario Wound Care Inc
University Health Network, Toronto
Layout table for investigator information
Study Chair: Daria O'Reilly, PhD Programs for Assessment of Technology in Health Research Institute
Principal Investigator: Ludwik Fedorko, MD Judy Dan Wound Care Centre/University Health Network
Principal Investigator: Ron Linden, MD Judy Dan Wound Care Centre/University Health Network

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ron Goeree, Director, St. Joseph's Healthcare Hamilton Identifier: NCT00621608    
Other Study ID Numbers: HTA011-0708-01
First Posted: February 22, 2008    Key Record Dates
Last Update Posted: May 9, 2013
Last Verified: May 2013
Keywords provided by Ron Goeree, St. Joseph's Healthcare Hamilton:
Chronic ulcers
Hyperbaric Oxygen Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pathologic Processes